NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.

Author: Kigajin Doull
Country: Dominican Republic
Language: English (Spanish)
Genre: History
Published (Last): 17 July 2014
Pages: 468
PDF File Size: 1.86 Mb
ePub File Size: 3.53 Mb
ISBN: 884-5-88558-508-1
Downloads: 76039
Price: Free* [*Free Regsitration Required]
Uploader: Vozahn

Abbott to pay $3.7 billion for unit of India’s Piramal

White, chairman and chief executive officer, Abbott. Fortis again pushes back date to complete RHT Health deal; auditor resigns. All the cash from the deal will go into Piramal Healthcare and will be invested in existing business segments such as consumer healthcare or the OTC unit, the critical care segment and drug research, chairman Piramal said.

Abbott has been operating in India for of its years, and has popular pharmaceutical brands including the antacid Digene and painkiller Brufen.

Country Garden, one of the largest and most successful vertically integrated real estate[…]. This abobtt the 2nd-largest deal ever in the Indian pharma industry, just behind Daiichi Sankyo’s takeover of Ranbaxy in Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities.

Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products. Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates Fujifilm Diosynth Biotechnologies adquisition announced it has abgott into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates ADCsa growing niche in the development of biopharmace India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon.


A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?

Piramal’s Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience.

To use all the functions on Chemie. The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry and invest in soluyions remaining business. But that is also changing, she says.

Piramal’s Healthcare Solutions business employs over 5, people in India. As Abbott wanted to make a significant presence in India, they feel it is reasonable. In the past few years, they have realized that those pipelines pf running dry, and are trying to diversify. Wharton professor of healthcare management Patricia Danzon agrees.

Abbott buys Piramal unit, tops table – Livemint

Abbott acquisition of St. According to Reuters, Abbott was advised by Morgan Stanley.

Abbott Gesellschaft mbH more. Piramal’s Healthcare Solutions business will become part of Abbott’s newly created, stand-alone Established Products Division.

We have sent you a verification email. We are the strategic consultancy of McCann Health. Read Post a comment. Refrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community.

For MNCs, emerging markets, with their cheaper generic medicines, are turning out to be the new battleground, given that most are witnessing stalled sales in Western markets. BOis booming as governments battle rising healthcare costs. We combine fresh and creative thinking with scientific and strategic depth Featured Today In Travel. For consumers, the great value in generics is getting it cheaper. Facts, background information, dossiers.

Abbott To Acquire Piramal Healthcare Unit For $B | VCCircle

It allows Abbott to commercialize two dozen Zydus Cadila drugs in 15 emerging markets. Additional Reading Management Finding the Virtue in Private Equity Firms Many view private equity firms as villainous actors intent on the singular goal of profit.


Analysts say the Indian firm will take time to incubate new businesses and even longer for returns to accrue. All news from India. Wharton management professor Saikat Chaudhuri says the relatively higher valuation makes sense for Abbott. More news by Abbott. Piramal justified the sale by saying that future value from the branded generics business would come from business growth outside India.

The announcement follows receipt of all regulatory clearances necessary for closing. Abbott said it was advised by Morgan Stanley, while Piramal said it did not have a financial advisor on the deal.

Abbott Laboratories Request information now. Announcing the deal on Friday, Ajay Piramal, chairman of Piramal Healthcare, reiterated his commitment to stay invested in the pharmaceuticals business, albeit in the OTC over-the-counter segment, drug discovery, critical care and diagnostics space. Expensive legal battles with patent holders, higher regulatory scrutiny after charges of poor manufacturing quality, and increased competition in the generics space have compelled Indian pharmaceuticals firms to look for buyers.

This deal will push Abbott to the number one slot in the Indian pharma landscape. Indian companies can hope to become truly global pharmaceutical companies only through drug discovery, says Piramal. Over the past ten years, Abbott has established a leading presence in emerging markets and now more than 20 per cent of the company’s total sales are generated in these growing economies. By comparison, Acqquisition trades at about 4.

The stock markets reacted negatively to the deal. It is paying roughly 8.

Related Posts